Fluidigm

Specialized single-cell "cores" are popping up to help scientists get the most out of new technologies.

The firm's full-year 2016 revenues fell 9 percent, also on lower instrument sales.

The firm reported preliminary declining revenues for both the fourth quarter and full-year 2016 reporting periods. 

The GenomeWeb Index stayed relatively flat in November, underperforming the Dow and Nasdaq for a second month in a row.

The partners have opened a new biorepository that will engage with clinical researchers and foster future personalized medicine efforts in the German capital.

The GenomeWeb Index, which fell nearly 9 percent in October, rebounded to a 1 percent gain in November, but still underperformed the Dow and Nasdaq.

The partners will co-market the GenomOncology GO Clinical Workbench to interpret data generated using Fluidigm's Juno NGS library prep workflow.

Sales of Helios instruments and genomics analytical consumables were lower than expected, pulling down revenues.

The GenomeWeb Index fell nearly 9 percent in October, doubling back on September's 5 percent gain and underperforming the Dow and the Nasdaq.

The South San Francisco, California-based firm said instrument revenues fell 39 percent, driven by lower-than-average sales of its Helios mass cytometry system.

Pages

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.